An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond.

McIntyre P, van den Biggelaar AHJ, Beard F, Nowlan M, Regan AK, Pearce R, Nolan T, Hughes C, Richmond P

Open source

DOI
10.3390/vaccines14090736
Published
2026 Aug 26
Container
Vaccines
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/vaccines14090736,
  title = {An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond.},
  author = {McIntyre P and van den Biggelaar AHJ and Beard F and Nowlan M and Regan AK and Pearce R and Nolan T and Hughes C and Richmond P},
  year = {2026},
  journal = {Vaccines},
  doi = {10.3390/vaccines14090736},
  url = {https://doi.org/10.3390/vaccines14090736}
}

RIS

TY  - JOUR
TI  - An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond.
AU  - McIntyre P
AU  - van den Biggelaar AHJ
AU  - Beard F
AU  - Nowlan M
AU  - Regan AK
AU  - Pearce R
AU  - Nolan T
AU  - Hughes C
AU  - Richmond P
PY  - 2026
JO  - Vaccines
DO  - 10.3390/vaccines14090736
UR  - https://doi.org/10.3390/vaccines14090736
ER  - 

APA

P, M., AHJ, V. D. B., F, B., M, N., AK, R., R, P., T, N., C, H., & P, R. (2026). An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond.. Vaccines. https://doi.org/10.3390/vaccines14090736

Source records